Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Overweight rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and increased the price target from $48 to $53.
December 19, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Derek Archila reaffirmed an Overweight rating on Rhythm Pharmaceuticals and raised the price target to $53, indicating a positive outlook on the stock.
The increase in price target by a major financial institution like Wells Fargo typically reflects a positive assessment of the company's future prospects and can lead to increased investor confidence. This often results in a short-term positive impact on the stock price as the market adjusts to the new information.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100